SCHEMBL479017

SCHEMBL479017

O=C1c2ccccc2C(=O)c2cc(CBr)ccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.66
RAB9A P51151 7/20 0.66
SMN1; SMN2 Q16637 6/20 0.66
ALDH1A1 P00352 6/20 0.66
MAPK1 P28482 5/20 0.66
LMNA P02545 4/20 0.66
MAPT P10636 3/20 0.66
L3MBTL1 Q9Y468 2/20 0.66
CYP1A2 P05177 2/20 0.53
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
HSP90AB1 P08238 2/20 0.50
CYP3A4 P08684 2/20 0.50
TSHR P16473 2/20 0.50
ELANE P08246 1/20 0.50
CDC25B P30305 1/20 0.50
TP53 P04637 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
PTPRC P08575 3/20 0.48
BCL2 P10415 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7962565 0.98 MAPK1 (0.63) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL11547344 0.91 NPC1 (0.56) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL7718941 0.89 NPC1 (0.64) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL5604805 0.84 NPC1 (0.61) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL8849638 0.81 S100A4 (0.59) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL9209968 0.81 NPC1 (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
Anthraquinone SCHEMBL28037262 0.80 ALDH1A1 (0.67) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL21416409 0.80 S100A4 (0.63) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL36840 0.79 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL41511 0.79 NPC1 (0.66) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387524-A1 METHOD AND SYSTEM FOR THE PRODUCTION OF DISINFECTION AND/OR STERILISATION SOLUTIONS ESTEVEZ COMPANY CARLOS (ES) 2025-12-25 US claimed
EP-4549429-A1 METHOD AND SYSTEM FOR THE PRODUCTION OF DISINFECTION AND/OR STERILISATION SOLUTIONS Universitat Jaume I (ES) 2025-05-07 EP claimed
CN-118791374-A Photosensitizer with anthraquinone aggregation-induced emission characteristic and preparation method thereof 广西大学 2024-10-18 CN claimed
CN-115745769-B Recycling treatment method and application of 2-ethyl anthraquinone production waste 山东裕滨新材料有限公司 2024-02-13 CN claimed
WO-2024003436-A1 METHOD AND SYSTEM FOR THE PRODUCTION OF DISINFECTION AND/OR STERILISATION SOLUTIONS UNIVERSITAT JAUME I (ES) 2024-01-04 WO claimed
CN-117323315-A Application of 2-bromomethylanthraquinone in preparation of candida albicans biomembrane inhibitor 中国药科大学 2024-01-02 CN claimed
CN-105017042-B The preparation method of anthraquinone and naphthoquinones quaternary ammonium salt with anti-leukocythemia function 福建医科大学附属协和医院 2017-06-30 CN claimed
EP-3985383-B1 ANALYTE SENSOR PARKER HANNIFIN CORP (US) 2026-03-11 EP disclosed
US-20250387524-A1 METHOD AND SYSTEM FOR THE PRODUCTION OF DISINFECTION AND/OR STERILISATION SOLUTIONS ESTEVEZ COMPANY CARLOS (ES) 2025-12-25 US disclosed
EP-4578286-A1 METHOD FOR THE PREPARATION OF WATER-FREE DISINFECTION AND STERILISATION AGENTS AND USE THEREOF Universitat Jaume I (ES) 2025-07-02 EP disclosed
EP-3594672-B1 ANALYTE SENSOR PARKER HANNIFIN CORP (US) 2025-06-11 EP disclosed
EP-4549429-A1 METHOD AND SYSTEM FOR THE PRODUCTION OF DISINFECTION AND/OR STERILISATION SOLUTIONS Universitat Jaume I (ES) 2025-05-07 EP disclosed
CN-118791374-A Photosensitizer with anthraquinone aggregation-induced emission characteristic and preparation method thereof 广西大学 2024-10-18 CN disclosed
EP-0670871-A1 OXYGEN SCAVENGERS INDEPENDENT OF TRANSITION METAL CATALYSTS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1995-09-13 EP disclosed
WO-1994012590-A1 OXYGEN SCAVENGERS INDEPENDENT OF TRANSITION METAL CATALYSTS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 1994-06-09 WO disclosed
US-5053431-A Antitumor-anticarcinogenic agents SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1991-10-01 US disclosed
EP-0298031-B1 SUBSTITUTED ANTHRAQUINONES AND CURABLE COMPOSITIONS CIBA-GEIGY AG (CH) 1991-04-10 EP disclosed
US-4966918-A ANTICARCINOGENIC AGENTS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1990-10-30 US disclosed
WO-1990008759-A1 DERIVATIVES OF CHRYSOPHANOL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1990-08-09 WO disclosed
EP-0298031-A1 Substituted anthraquinones and curable compositions CIBA-GEIGY AG (CH) 1989-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387524-A1 METHOD AND SYSTEM FOR THE PRODUCTION OF DISINFECTION AND/OR STERILISATION SOLUTIONS HAO2, PDK3, ADH1C NPC1 4485/4885RAB9A 3495/4885SMN1; SMN2 4422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.